|

Intermittent PD-1/PD-L1 ICI + VEGFR-TKI Clinical Trials

1 actively recruiting trial

Also known as: Treatment pause

Pipeline

Phase 2: 1

Top Sponsors

  • Jinling Hospital, China1

Indications

  • Metastatic Renal Cell Carcinoma (mRCC)1
  • Renal Cell Carcinoma (RCC)1
  • Cancer1

Other1 trial

PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.